As of now, senomorphics are primarily in the research and development phase. However, some compounds known to have senomorphic activity, such as metformin and rapamycin, are being studied for their potential to modulate senescence in cancer therapy. These compounds have shown promise in preclinical studies, but further clinical trials are needed to confirm their efficacy and safety in humans.